Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2011
Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection.
Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 17 registered trials, which are not on this map. Cited by 393 papers, 11 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Hyperimmune Intravenous Immunoglobulin Treatment for Severe H1N1 2009 Infection
Collection of Plasma From Subjects That Recovered From or Were Vaccinated To Emerging Infectious Diseases
A Double-blind Randomised Controlled Trial on Flufenamic Acid for Hospitalised Influenza Infection
Plasma From Donors Recovered From New Coronavirus 2019 As Therapy For Critical Patients With Covid-19
Efficacy and Safety of Treatment With Convalescent Plasma for Adults With COVID-19 Pneumonia. A Double-blinded, Randomized, Multicenter Placebo-controlled Trial
Experimental Use of Convalescent Plasma for Passive Immunization in Current COVID-19 Pandemic in Pakistan in 2020
Use of Convalescent Plasma Therapy for COVID-19 Patients With Hypoxia: a Prospective Randomized Trial
Phase II, Randomized, Double-blind, Controlled Clinical Trial Evaluating the Efficacy and Safety of Plasma From Patients Cured of COVID-19 Compared to the Best Available Therapy in Subjects With SARS-CoV-2 Pneumonia
Passive Immunity Trial for Our Nation (PassItOn)
Evaluation Of Efficacy Of COVID-19 Convalescent Plasma Versus Standard Plasma In The Early Care Of COVID-19 Patients Hospitalized Outside Intensive Care Units.
Plasma From Covalescent Donors With Covid-19 for the Management of Patients With SARS-COV-2 Fase II and III, a Doble Center Randomized Doble Blind Trial
Treatment of Severe and Critical COVID-19 Pneumonia With Convalescent Plasma
Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma
Convalescent Plasma Treatment in COVID-19 Patients at a Tertiary Care Center in Pakistan
Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma Collected From Individuals With Documented Infection and Recovery From COVID-19 (SARS-CoV-2)
Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection
Convalescent Plasma for Passive Immunization in COVID-19 ICU Patients: An Interventional Study
Who cites it
393 citing papers in PubMed, 11 syntheses or guidelines pooled it, 713 citations in OpenAlex.
- Lessons learned from the use of convalescent plasma for the treatment of COVID-19 and specific considerations for immunocompromised patients.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2022Pooled it
- COVID-19-Associated acute respiratory distress syndrome (CARDS): Mechanistic insights on therapeutic intervention and emerging trends.International immunopharmacology · 2021Pooled it
- Current views on the potentials of convalescent plasma therapy (CPT) as Coronavirus disease 2019 (COVID-19) treatment: A systematic review and meta-analysis based on recent studies and previous respiratory pandemics.Reviews in medical virology · 2021Pooled it
- Bioethical perspective of convalescent plasma therapy for COVID-19: A systematic review.Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine · 2021Pooled it
- The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis.Mayo Clinic proceedings · 2021Pooled it
- Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis.JMIR public health and surveillance · 2021Pooled it
- Convalescent plasma may be a possible treatment for COVID-19: A systematic review.International immunopharmacology · 2021Pooled it
- Convalescent plasma is a clutch at straws in COVID-19 management! A systematic review and meta-analysis.Journal of medical virology · 2021Pooled it
- Assessment of the Safety and Therapeutic Benefits of Convalescent Plasma in COVID-19 Treatment: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2021Pooled it
- Effect of convalescent blood products for patients with severe acute respiratory infections of viral etiology: A systematic review and meta-analysis.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021Pooled it
- Mortality Benefit of Convalescent Plasma in COVID-19: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2021Pooled it
- The effect of early COVID-19 treatment with convalescent plasma on antibody responses to SARS-CoV-2.Microbiology spectrum · 2025Trial
- Efficacy of convalescent plasma in hospitalized COVID-19 patients: findings from a controlled trial.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2024Trial
- Convalescent or standard plasma versus standard of care in the treatment of COVID-19 patients with respiratory impairment: short and long-term effects. A three-arm randomized controlled clinical trial.BMC infectious diseases · 2022Trial
- A randomized placebo-controlled trial of convalescent plasma for adults hospitalized with COVID-19 pneumonia.Scientific reports · 2022Trial
- Efficacy of convalescent plasma therapy in the patient with COVID-19: a randomised control trial (COPLA-II trial).BMJ open · 2022Trial
- High-Dose Convalescent Plasma for Treatment of Severe COVID-19.Emerging infectious diseases · 2022Trial
- Evaluation of a COVID-19 convalescent plasma program at a U.S. academic medical center.PloS one · 2022Trial
- Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in Southern Sweden.BMC research notes · 2021Trial
- Detection of SARS-CoV-2-independent immunoregulatory activity of COVID-19 convalescent plasma.Transfusion · 2021Trial
333 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 13 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExperience from treating patients with Spanish influenza and influenza A(H5N1) suggested that convalescent plasma therapy might be beneficial. However, its efficacy in patients with severe pandemic influenza A(H1N1) 2009 virus (H1N1 2009) infection remained unknown.
methodsDuring the period from 1 September 2009 through 30 June 2010, we conducted a prospective cohort study by recruiting patients aged ≥ 18 years with severe H1N1 2009 infection requiring intensive care. Patients were offered treatment with convalescent plasma with a neutralizing antibody titer of ≥ 1:160, harvested by apheresis from patients recovering from H1N1 2009 infection. Clinical outcome was compared with that of patients who declined plasma treatment as the untreated controls.
resultsNinety-three patients with severe H1N1 2009 infection requiring intensive care were recruited. Twenty patients (21.5%) received plasma treatment. The treatment and control groups were matched by age, sex, and disease severity scores. Mortality in the treatment group was significantly lower than in the nontreatment group (20.0% vs 54.8%; P = .01). Multivariate analysis showed that plasma treatment reduced mortality (odds ratio [OR], .20; 95% confidence interval [CI], .06-.69; P = .011), whereas complication of acute renal failure was independently associated with death (OR, 3.79; 95% CI, 1.15-12.4; P = .028). Subgroup analysis of 44 patients with serial respiratory tract viral load and cytokine level demonstrated that plasma treatment was associated with significantly lower day 3, 5, and 7 viral load, compared with the control group (P < .05). The corresponding temporal levels of interleukin 6, interleukin 10, and tumor necrosis factor α (P < .05) were also lower in the treatment group.
conclusionsTreatment of severe H1N1 2009 infection with convalescent plasma reduced respiratory tract viral load, serum cytokine response, and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.